How to Slow Chronic Kidney Disease Progression

Slowing chronic kidney disease depends on a layered strategy: controlling blood pressure, reducing the protein leak in urine, protecting remaining kidney tissue from overwork, and managing the metabolic fallout that accompanies declining filtration. No single drug or lifestyle change does all of this alone. Over the past decade, several medications have moved from “promising” to “proven,” and combining them with dietary adjustments and careful avoidance of kidney-toxic exposures gives people with CKD a realistic shot at delaying or even preventing kidney failure.

Why CKD Tends to Get Worse on Its Own

Understanding why kidneys keep declining even after the original injury is gone helps explain why the treatments below work. Each kidney contains hundreds of thousands of tiny filtering units called nephrons. When some nephrons are damaged or destroyed, the surviving ones compensate by filtering more aggressively. That compensatory overwork raises pressure inside each remaining filter and forces the nephrons to enlarge.¹ In the short run this maintains your overall kidney function. In the long run it damages those surviving nephrons, causing more protein to spill into the urine and triggering inflammation and scarring in the surrounding tissue.² The result is a vicious cycle: nephron loss leads to overwork, overwork leads to more nephron loss.

Protein leaking through damaged filters also harms the kidney’s drainage tubes. The excess protein overloads the tubular cells, sparks local inflammation, and promotes fibrosis, which is essentially scar tissue replacing functional kidney.³ Nearly every effective treatment for CKD progression targets some piece of this cycle: lowering the pressure inside the filters, reducing proteinuria, or dampening the inflammatory and fibrotic response.

ACE Inhibitors and ARBs

These blood pressure medications have been the backbone of CKD treatment for decades, and for good reason. ACE inhibitors and angiotensin receptor blockers (ARBs) specifically relax the tiny blood vessel leaving each glomerular filter. By widening that exit vessel, they reduce the hydraulic pressure inside the filter itself, which directly addresses the hyperfiltration problem.⁴ The drop in intraglomerular pressure translates into less protein leaking into the urine, less tubular overload, and a slower rate of kidney function decline.

If you have CKD with any amount of protein in your urine and no specific reason you cannot take these drugs, an ACE inhibitor or ARB is typically the first medication prescribed. They also lower systemic blood pressure, which matters because uncontrolled hypertension is one of the strongest accelerators of kidney damage. One practical note: when you first start one of these medications, your kidney function numbers may dip slightly. That initial dip reflects the intended drop in filtration pressure and is usually not a reason to stop the drug. Your doctor will recheck your labs a couple of weeks after starting to make sure the dip is modest and your potassium stays in range.

SGLT2 Inhibitors

Originally developed for diabetes, SGLT2 inhibitors (drugs like empagliflozin, dapagliflozin, and canagliflozin) have turned out to be one of the most significant advances in kidney protection in years. They work through a different mechanism than ACE inhibitors. By blocking glucose and sodium reabsorption in the kidney’s proximal tubule, they trigger a feedback signal that constricts the vessel entering the filter, reducing intraglomerular pressure from the other side.⁵ This effect happens regardless of whether you have diabetes, which is why these drugs are now approved for CKD broadly.

A recent meta-analysis found that SGLT2 inhibitors slowed the annual decline in kidney filtration rate, reduced albuminuria by about 37%, cut the risk of kidney failure by roughly 30%, and lowered the risk of a major doubling in creatinine by about a third.⁶ The canagliflozin CREDENCE trial was among the first to demonstrate kidney-specific benefits in people with type 2 diabetes and established kidney disease, and subsequent trials have extended those results to people without diabetes.⁷

Like ACE inhibitors, SGLT2 inhibitors cause an expected initial dip in filtration rate that reflects reduced hyperfiltration. This dip stabilizes and, over months, the treated group’s kidney function holds steady while the untreated group continues to decline. Common side effects include genital yeast infections and, less frequently, urinary tract infections. These are usually manageable and rarely a reason to stop a drug that carries this much kidney-protective benefit.

Finerenone and Mineralocorticoid Receptor Antagonists

Aldosterone, a hormone that regulates salt and water balance, also drives inflammation and fibrosis in the kidney. Older mineralocorticoid receptor blockers like spironolactone were limited in CKD because they raised potassium levels to dangerous levels too often. Finerenone is a newer, nonsteroidal version designed to block the inflammatory and fibrotic effects of aldosterone with a more favorable safety profile.

In people with type 2 diabetes and CKD, finerenone reduced the risk of a composite kidney outcome (including kidney failure and sustained filtration decline) by about 23%, and cardiovascular events by about 14%.⁸ Across larger pooled analyses involving more than 13,000 participants, these benefits were consistent across subgroups.⁹ Finerenone still raises potassium to some degree, so regular lab monitoring is essential, but the risk is lower than with the older drugs. For now, the strongest evidence applies to people with diabetic kidney disease who are already on an ACE inhibitor or ARB.

GLP-1 Receptor Agonists

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, and others) are best known for treating diabetes and obesity, but their kidney-protective effects have attracted serious attention. A large systematic review of randomized trials found that in people with type 2 diabetes, GLP-1 receptor agonists reduced a composite kidney outcome by about 18%, kidney failure by 16%, major cardiovascular events by 13%, and all-cause death by 12%.¹⁰ These benefits appear to extend beyond glucose control alone, though the precise kidney mechanisms are still being mapped.¹¹

Early evidence also suggests that combining a GLP-1 receptor agonist with an SGLT2 inhibitor may offer additive benefits. One study found that the combination achieved greater reductions in urine albumin than either drug alone.¹² This idea of stacking complementary medications on top of an ACE inhibitor or ARB is increasingly how nephrologists think about CKD management in people with diabetes: each drug addresses a slightly different piece of the progression puzzle.

Dietary Protein and Sodium

Reducing how much protein you eat is one of the oldest strategies for slowing CKD, and the evidence is more nuanced than you might expect. A large Cochrane review found that a very-low-protein diet (supplemented with amino acid analogues called ketoanalogues) probably reduces the number of people reaching kidney failure, while a standard low-protein diet alone made little measurable difference in larger studies.¹³ The logic is straightforward: less protein means less work for each nephron, less filtration pressure, and less protein debris in the tubules. One retrospective study found that patients who responded best to a low-protein diet supplemented with ketoanalogues were those who started with higher dietary protein intake and higher urinary phosphate excretion, suggesting the intervention helps most when there is more excess to trim.¹⁴

Sodium restriction matters for a different reason. High salt intake raises blood pressure and blunts the protective effect of ACE inhibitors and ARBs. In people with CKD who are not yet on dialysis, cutting salt lowers blood pressure and enhances the anti-proteinuric effect of their medications.¹⁵ Most guidelines recommend keeping sodium under about 2,000 milligrams per day. This is challenging in practice because so much sodium hides in processed and restaurant food, but even a partial reduction helps.

Correcting Metabolic Acidosis

As kidney function drops, the kidneys lose their ability to excrete acid efficiently, and blood becomes slightly too acidic. This metabolic acidosis accelerates muscle wasting, bone loss, and kidney decline. Supplementing with oral sodium bicarbonate, which is essentially baking soda in tablet form, can correct the acid buildup and meaningfully slow CKD progression.

A landmark study found that bicarbonate supplementation dramatically slowed the rate of kidney function decline compared with no supplementation. Rapid progression was far less common in the treated group, and substantially fewer patients on bicarbonate reached kidney failure.¹⁶ A meta-analysis confirmed these findings, showing that oral sodium bicarbonate significantly slowed eGFR decline compared with control groups.¹⁷ A separate five-year study in people with hypertension-related kidney disease found that daily sodium bicarbonate preserved kidney function better than placebo or sodium chloride, confirming that the benefit comes from the bicarbonate ion itself, not just the sodium.¹⁸

Most nephrologists now check serum bicarbonate levels regularly and supplement when they fall below about 22 mEq/L. Increasing fruits and vegetables, which are metabolized into bicarbonate, is a dietary alternative that some patients tolerate better than tablets.

Statins and Kidney Function

People with CKD are far more likely to die of heart disease than to reach dialysis, so cardiovascular risk management is not a side concern but a central one. Dyslipidemia is common in CKD, and statins appear to help the kidneys through both cholesterol-lowering and anti-inflammatory pathways.¹⁹ A meta-analysis of statin use in people with stage 3 or 4 CKD found that statins slowed the decline in kidney function compared with placebo, in both people with and without prior cardiovascular events.²⁰ While the kidney benefit of statins is more modest than what you get from SGLT2 inhibitors or ACE inhibitors, the cardiovascular protection alone justifies their use in most people with CKD.

The Uric Acid Question

For years, high uric acid levels were suspected of driving CKD progression, and some smaller studies supported the use of allopurinol to lower uric acid in people with kidney disease. Then a large, well-designed trial put the idea to a rigorous test. The CKD-FIX trial found that allopurinol did not slow eGFR decline compared with placebo; the rate of kidney function loss was virtually identical in both groups.²¹

That said, some observational and smaller interventional data suggest that managing hyperuricemia through a combination of diet and medication may improve filtration rate in certain CKD patients with clearly elevated uric acid.²² The current consensus is that routine uric acid lowering specifically to protect the kidneys is not supported by the best available evidence, though treating gout or symptomatic hyperuricemia in someone with CKD is still perfectly appropriate for other reasons.

Avoiding Kidney-Toxic Exposures

Some of the most effective kidney protection is not about adding medications but about removing harmful exposures. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen are among the most common offenders. They work by blocking prostaglandins that help maintain blood flow to the kidney, which can cause acute injury in the short term and accelerate CKD over the long term.²³ In people with hypertension, using NSAIDs for 90 days or more was associated with about a 32% higher risk of developing CKD compared with non-users.²⁴ The risk is highest in people who already have kidney disease, heart failure, or liver disease, or who take other medications that affect kidney blood flow.²⁵ If you have CKD, acetaminophen (paracetamol) is generally the safer choice for pain, though it is worth discussing alternatives with your doctor for chronic pain conditions.

Smoking accelerates CKD progression through several pathways: it raises blood pressure, promotes vascular inflammation, and directly impairs kidney blood flow. Quitting is easier said than done, but structured cessation programs designed for CKD patients have shown meaningful improvements in quit rates.²⁶

Tracking Progress With Albuminuria

If you are doing all of the above, how do you know it is working? Kidney function measured by eGFR declines slowly, so changes can take months or years to detect. Albuminuria, the amount of the protein albumin leaking into urine, responds to treatment more quickly and serves as an early signal of whether things are headed in the right direction.

A meta-analysis found that for every 30% reduction in urine albumin, the risk of reaching a hard kidney endpoint dropped by roughly 19%.²⁷ In people with type 2 diabetes, those whose albumin-to-creatinine ratio dropped by more than 30% had roughly half the risk of kidney failure compared with those whose ratio stayed flat, while those whose ratio rose by more than 30% had more than double the risk.²⁸ Practically, this means a urine albumin-to-creatinine ratio checked every few months gives you and your doctor a running scorecard. If albuminuria is dropping, the treatment plan is working. If it is rising despite treatment, something needs to change.

Endothelin Receptor Antagonists on the Horizon

Beyond the drugs already in widespread use, endothelin receptor antagonists are an emerging class worth knowing about. Endothelin-1 is a molecule that constricts blood vessels and promotes kidney inflammation and scarring. Blocking its receptor with drugs like atrasentan has reduced albuminuria and slowed kidney function decline in people with diabetic CKD. A newer agent called sparsentan, which blocks both the endothelin A receptor and the angiotensin receptor in a single pill, preserved kidney function with minimal fluid retention in patients with IgA nephropathy, a common cause of CKD in younger adults.²⁹ Another approach combines a low-dose endothelin blocker (zibotentan) with the SGLT2 inhibitor dapagliflozin, which enhanced albuminuria reduction while the SGLT2 inhibitor counteracted the fluid retention that has historically been a problem with endothelin blockers.³⁰ These agents are not yet part of standard care for most CKD patients, but trials are ongoing and they may soon add another layer to the treatment stack.

Phosphate, FGF23, and Mineral Balance

As kidneys lose function, they struggle to excrete phosphate, and blood phosphate levels creep upward. The body responds by ramping up a hormone called FGF23, which tries to force extra phosphate out through the remaining nephrons. Chronically elevated FGF23 is linked to cardiovascular disease and further kidney damage. Phosphate binders, medications taken with meals that trap dietary phosphate in the gut before it can be absorbed, can reduce FGF23 levels in people with CKD.³¹ However, a meta-regression in that same analysis found that high dietary phosphate intake blunted the effect of the binders, which underscores why dietary phosphate restriction and binder use go hand in hand. Among specific binders, lanthanum carbonate was effective at reducing both phosphate load and FGF23 levels in advanced CKD, while calcium carbonate was not.³²

Sleep Apnea and Kidney Disease

Obstructive sleep apnea is surprisingly common in people with CKD and can quietly accelerate kidney decline. The repeated drops in oxygen during sleep trigger surges in sympathetic nervous system activity, which in turn activates the renin-angiotensin-aldosterone system and drives blood pressure higher.³³ Because many of the kidney-protective medications discussed above work by dampening that same hormonal system, untreated sleep apnea can undermine their effectiveness. If you snore heavily, wake unrefreshed, or have been told you stop breathing during sleep, getting tested and treated could be an underappreciated way to help protect your kidneys.

Birth Weight and Nephron Endowment

Not everyone starts life with the same number of nephrons. Human nephron counts vary enormously, ranging from under half a million to over two million per kidney, and a large portion of that variability is established before birth.³⁴ About 60% of nephrons form in the third trimester of pregnancy, so premature birth or low birth weight can leave a person with a permanently smaller nephron reserve. Research has found a strong correlation between birth weight and nephron count, with roughly 175,000 additional nephrons per kilogram of birth weight.³⁵

A person born with fewer nephrons has less kidney reserve to absorb future hits from diabetes, hypertension, or aging. The remaining nephrons must work harder from the start, setting up the same hyperfiltration cycle described earlier, just sooner.³⁶ This is not something you can change after the fact, but it helps explain why some people develop CKD without an obvious cause, and it argues for earlier and more aggressive screening in people with a history of low birth weight or prematurity.

The Gut Microbiome Connection

CKD changes the composition of gut bacteria in ways that feed back into kidney and cardiovascular damage. As the kidneys fail to clear waste products, urea and other retained toxins flood the intestine, favoring bacteria that produce harmful compounds like indoxyl sulfate, p-cresyl sulfate, and TMAO. At the same time, the number of bacteria that produce short-chain fatty acids, which nourish the gut lining, declines.³⁷ The gut lining becomes inflamed, its junctions loosen, and those uremic toxins leak into the bloodstream where they promote vascular calcification, worsen kidney fibrosis, impair immune function, and contribute to insulin resistance. This “gut-kidney axis” is an active area of research, and while no definitive microbiome-targeted therapy exists yet, strategies like increasing dietary fiber, reducing processed food, and possibly using prebiotics may help by shifting the bacterial balance toward species that produce fewer toxins and more protective short-chain fatty acids.